In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

Executive Summary

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

You may also be interested in...



Lilly/BI's Jardiance Scores A Win In Heart Failure Where Rivals Have Not

A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.

Boehringer Reflects On Resilience Of Older Therapies

The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.

Boehringer Ingelheim To Focus On Precision Psychiatry In CNS

Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV124844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel